{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Tb-500",
    "short_name": "TB-500",
    "aliases": [
      "tb 500",
      "TB500",
      "Thymosin Beta-4 fragment"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Unapproved peptide commonly discussed in recovery contexts. Often conflated with Thymosin Beta-4 (Tβ4) biology; products vary and claims frequently exceed evidence."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "TB-500 is not an approved therapeutic drug. Evidence for many recovery claims is primarily preclinical; human evidence for TB-500 specifically is limited."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 6,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "animal",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Key uncertainty is that many benefits are inferred from broader thymosin beta-4 biology and animal work, while real-world risk includes sourcing purity and unregulated administration. Developmental risk flagged due to common youth-athlete interest and limited safety characterization.",
      "risk_score": 6
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "low",
          "evidence_grade": "animal",
          "text": "TB-500 is a peptide product marketed in recovery contexts, often linked to thymosin beta-4 biology. Many claims rely on preclinical data; human outcome evidence for TB-500 as sold is limited.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "varies",
          "unit": "study-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. This app does not provide protocols. Not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "title": "Developmental / Adolescent risk",
          "population_group": "adolescent",
          "confidence": "low",
          "evidence_grade": "unknown",
          "text": "Because TB-500 claims are often preclinical and safety is not well characterized, adolescents should treat uncertainty as meaningful risk, especially given real-world sourcing variability.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a peptide product marketed in recovery contexts, often linked to thymosin beta-4 biology",
        "tendon and ligament recovery support",
        "soft tissue healing after overuse or injury",
        "return-to-training support during rehab",
        "joint comfort and mobility support",
        "interest in tissue repair pathways"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Thymosin beta-4 biology and tissue repair (review; context for claims)",
        "source_type": "pmc",
        "source_id": "PMC4007404",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4007404/",
        "published_date": "2014-01-01",
        "evidence_grade": "animal",
        "notes": "Broad review of thymosin beta-4 biology; supports mechanistic plausibility in animals but does not establish TB-500 outcomes in humans.",
        "year": 2014
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for TB-500",
        "detail": "Added recovery-context peptide entry with strong preclinical framing; flagged developmental risk and sourcing uncertainty.",
        "evidence_refs": [
          "E1"
        ]
      }
    ],
    "meta": {
      "appears_in_blends": [
        "bpc-157-tb-500",
        "glow",
        "klow"
      ]
    },
    "topics": {
      "primary": [
        "topic_injury_healing",
        "topic_muscle_recovery"
      ]
    },
    "slug": "tb-500",
    "practical": {
      "schema_version": "practical_block_v1",
      "bottom_line": "TB-500 is a market name often associated with thymosin beta-4–related fragments and is commonly discussed for injury recovery. Most supportive data is preclinical or indirect, and real-world risk is driven by product identity confusion and unregulated sourcing.",
      "benefits": [
        "Soft-tissue recovery interest after overuse or injury",
        "Return-to-training support interest during rehab periods",
        "Joint comfort and mobility support interest in recovery discussions"
      ],
      "side_effects_common": [
        "Injection-site irritation or discomfort",
        "Headache",
        "Nausea",
        "Fatigue"
      ],
      "side_effects_serious": [
        "Allergic reaction with hives, facial swelling, or trouble breathing",
        "Chest pain, fainting, or severe shortness of breath",
        "Severe swelling, rapidly spreading redness, or drainage at an injection site"
      ],
      "who_should_be_cautious": [
        "Active cancer or recent cancer treatment",
        "People using anticoagulants or antiplatelets",
        "Bleeding disorders",
        "Pregnancy or breastfeeding",
        "Children and adolescents"
      ]
    }
  },
  "canonical_name": "Tb-500",
  "interactions": {
    "drug_classes": [
      "anticoagulants-antiplatelets"
    ],
    "supplement_classes": [
      "anticoagulant-herbs"
    ],
    "peptides": []
  },
  "practical": {
    "bottom_line": "TB-500 is marketed as a recovery peptide linked to thymosin beta-4 fragments. Real-world use centers on soft-tissue recovery claims; human evidence is limited.",
    "benefits": [
      "soft-tissue recovery discussions (anecdotal, evidence limited)",
      "general “inflammation control” claims in some communities (often overstated)",
      "sometimes grouped with other injury-healing compounds in recovery culture"
    ],
    "side_effects_common": [
      "fatigue",
      "headache",
      "nausea"
    ],
    "side_effects_serious": [
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)",
      "persistent chest pain, fainting, or severe shortness of breath"
    ],
    "who_should_be_cautious": [
      "people with active cancer or a high cancer-risk history (tissue-growth signaling context)",
      "pregnant or breastfeeding individuals",
      "adolescents (limited evidence and developmental uncertainty)",
      "anyone using unverified sources (contamination and mislabeling risk)"
    ],
    "schema_version": "practical_block_v1"
  }
}
